Market Place
Sourcing Support
Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
29 Jun 2023 //
GLOBENEWSWIRE
Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
19 May 2023 //
GLOBENEWSWIRE
Calithera Announces Board Approval of Complete Liquidation and Dissolution
09 Jan 2023 //
GLOBENEWSWIRE
Calithera to shut down after failing to revive Takeda assets
09 Jan 2023 //
ENDPTS
Calithera Biosciences Reports 3Q 2022 Financial Results and Business Update
14 Nov 2022 //
GLOBENEWSWIRE
Calithera Biosciences to Report3Q 2022 Financial Results on Monday, Nov 14, 2022
08 Nov 2022 //
GLOBENEWSWIRE
Calithera Receives FDA Fast Track Designation for Sapanisertib
03 Oct 2022 //
GLOBENEWSWIRE
Calithera to Present at the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Calithera Biosciences Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Calithera Biosciences to Report Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Calithera Bio Shares Progress in Sapanisertib and Mivavotinib Clinical Programs
13 Jul 2022 //
GLOBENEWSWIRE
Calithera Bio Begins Dosing in PII Trial of Sapanisertib in r/r NRF2-msNSCLC
06 Jul 2022 //
GLOBENEWSWIRE
Calithera Bio Begins Enrollment in PII Trial of Mivavotinib in r/r ABC DLBCL
23 Jun 2022 //
GLOBENEWSWIRE
Calithera Biosciences Announces 1-for-20 Reverse Stock Split
14 Jun 2022 //
GLOBENEWSWIRE
Calithera to Present at the H.C. Wainwright Global Investment Conference
17 May 2022 //
GLOBENEWSWIRE
Calithera Biosciences Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Calithera Biosciences to Report First Quarter 2022 Financial Results
03 May 2022 //
GLOBENEWSWIRE
Calithera Shows Data on Discovery of Promising Synthetic Lethal Compounds
08 Apr 2022 //
GLOBENEWSWIRE
Calithera Bio Reports Fourth Quarter and Full Year 2021 Financial Results
31 Mar 2022 //
GLOBENEWSWIRE
Calithera Bio Prices $10M Underwritten Public Offering of Common Stock
30 Mar 2022 //
GLOBENEWSWIRE
Calithera Bio Commences Underwritten Public Offering of Common Stock
29 Mar 2022 //
GLOBENEWSWIRE
Calithera Bio to Report Q4 and Full Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
Calithera to Present Data Highlighting Synthetic Lethal Target VPS4 at AACR
08 Mar 2022 //
GLOBENEWSWIRE
Calithera to suspend Phase II NSCLC trial due to lack of clinical benefit
08 Nov 2021 //
CLINICALTRIALSARENA
Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
05 Nov 2021 //
GLOBENEWSWIRE
Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280
01 Nov 2021 //
GLOBENEWSWIRE
Calithera Biosciences to Present First Clinical Data from Development Program
21 Oct 2021 //
GLOBENEWSWIRE
Struggling Calithera nabs 2 cheap cancer assets from Takeda
20 Oct 2021 //
THEPHARMALETTER
Calithera Expands Oncology Pipeline with Acquisition Two Clinical-Stage Assets
18 Oct 2021 //
GLOBENEWSWIRE
Calithera Biosciences to Participate in Two Upcoming Investor Conferences
01 Sep 2021 //
BIO SPACE
Calithera Biosciences Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Calithera Report Second Quarter 2021 Financial Results on August 5, 2021
29 Jul 2021 //
GLOBENEWSWIRE
Final Data from Calithera Biosciences’ Ph2 CANTATA Study Presented at 2021 ASCO
07 Jun 2021 //
GLOBENEWSWIRE
Calithera Biosciences and Antengene Enter Worldwide License Agreement
17 May 2021 //
GLOBENEWSWIRE
Results from Calithera Biosciences’ CANTATA Study to Be Presented at 2021 ASCO
28 Apr 2021 //
GLOBENEWSWIRE
Slammed with PhII flop for lead drug, Calithera lays off a third of its staffers
05 Jan 2021 //
ENDPTS
Calithera Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma
04 Jan 2021 //
YAHOO
Calithera Biosciences Announces New Employment Inducement Grants
01 Dec 2020 //
GLOBENEWSWIRE
Calithera Biosciences Presents New Preclinical Data for CB-668 at (SITC)
09 Nov 2020 //
GLOBENEWSWIRE
Calithera Announces Expansion of Ongoing Trial Evaluating Telaglenastat
04 Nov 2020 //
GLOBENEWSWIRE
Calithera Awarded up to $2.4M from Cystic Fibrosis Foundation
02 Nov 2020 //
GLOBENEWSWIRE
Calithera Biosciences’ CB-280 Arginase Inhibitor Trial in Progress Poster
07 Oct 2020 //
GLOBENEWSWIRE
Calithera Biosciences Initiates KEAPSAKE Randomized PhII Trial of Telaglenastat
24 Sep 2020 //
BIOSPACE
